#$%^&*AU2018204223A120180705.pdf#####Abstract The present invention relates to a topical pharmaceutical composition comprising acitretin and a process for its preparation. It also relates to a method of treating skin disorders by administering said topical pharmaceutical composition.1/2 Figure 1: Mean Utriculi Size after Application of Various Strengths of Acitretin Gels and Tazorac* (Tazarotene) Gel 3aIOm Mean Utriculi Size 2aaaOO E Lac am -- - -- -- F Control Placebo 0.02% 0.05% 0.16% 0.20% "r FE Utr icili Size 255,38 1233.61 1109.52 160.30 163-64 157.46 45..,2/2 Figure 2: Percentage Reduction in Utriculi Size After Application of Various Strengths of Acitretin Gels and Tazorac® (Tazarotene) Gel With Respect to Control .w O% Reduction in Utriculi Size 70 to E 60 E C S 50 40 I* :30 20 10 Control Placebo 0.02% 0.05% 0.10% 0.20% Tazorc ERedactiox % 0 &53 57.12 76.39 7508 77.50 82.19
